At $2M per shot, ICER says two new sickle cell gene therapies could be cost-effective

Zachary Brennan

Senior Editor

Gene therapies approved by the FDA have so far brought with them eye-popping prices of $2 million or more because of the extraordinary savings, sometimes …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

At $2M per shot, ICER says two new sickle cell gene therapies could be cost-effective

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

At $2M per shot, ICER says two new sick­le cell gene ther­a­pies could be cost-ef­fec­tive

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

At $2M per shot, ICER says two new sickle cell gene therapies could be cost-effective